<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00067782</url>
  </required_header>
  <id_info>
    <org_study_id>AI424-067</org_study_id>
    <nct_id>NCT00067782</nct_id>
  </id_info>
  <brief_title>A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to learn if atazanavir is associated with
      serum LDL cholesterol in HIV-infected subjects following a substitution of atazanavir for
      their previously administered protease inhibitor.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to virologic rebound for subjects with HIV RNA &lt; 50 c/mL at baseline; Magnitude/ durability of increases from baseline in absolute CD4 (Time-Averaged Difference) through WK12; Mean % change from baseline in fasting LDL cholesterol at WK12.</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir (immediate switch)</intervention_name>
    <description>Capsules, Oral, 400mg, Once daily, 48 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Reyataz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir (Week 24 switch)</intervention_name>
    <description>Capsules, Oral, 400mg, Once daily, 48 weeks.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Reyataz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must be on current HIV treatment regimen at least 3 to 6 months prior to study (this
             must be one protease inhibitor, or ritonavir-boosted protease inhibitor, and two
             nucleoside reverse transcriptase inhibitors) must be subject's first PI ever received

          -  Plasma HIV-1 RNA level &lt; 50 c/mL within 3 to 6 months prior to study start

          -  Fasting LDL cholesterol &gt; 130 mg/dL

        Key Exclusion Criteria:

          -  WOCBP who do not use effective barrier contraception for any reason

          -  Women who are pregnant or breast feeding

          -  A life expectancy &lt; 12 months

          -  Presence of a newly diagnosed HIV-related OI or any medical condition requiring acute
             therapy at the time of enrollment

          -  Cushing's Syndrome

          -  Uncontrolled diabetes mellitus, history of diabetic ketoacidosis or hyperosmolar
             syndrome

          -  Untreated hypothyroidism or hyperthyroidism

          -  Nephrotic syndrome or significant proteinuria

          -  Obstructive liver disease

          -  Active alcohol or substance abuse

          -  Proven or suspected acute hepatitis in the 30 days prior to study entry

          -  Intractable diarrhea (greater than or equal to 6 loose stools/day for at least 7
             consecutive days) within 30 days prior to study start

          -  History of acute or chronic pancreatitis

          -  Inability to swallow capsules

          -  Presence of cardiomyopathy

          -  Known history of prolonged QTc interval

          -  Any of the following:

               1. clinical symptoms potentially related to heart block

               2. heart rate &lt; 40 bpm

               3. any of the following EKG abnormalities:

             i) pause length &gt; 3 seconds ii) second or third degree AV heart block iii) QTc
             interval &gt; 450 msec for males iv) QTc interval &gt; 470 msec for females

          -  Fasting serum triglyceride level &gt; 750 mg/dL

          -  Any of the following lab values within 2 weeks of starting study drug:

               1. serum creatinine greater to or equal to 1.5 times the upper limit of normal

               2. total serum lipase greater than or equal to 1.4 times the upper limit of normal

               3. liver transaminases greater than or equal to 3 times the upper limit of normal

               4. total serum bilirubin greater than or equal to 1.5 times the upper limit of
                  normal

          -  Hypersensitivity to any component of the formulation of study drug

          -  Use of any lipid-lowering agent within 4 weeks prior or during study

          -  Use of a PI-containing ARV regimen prior to entry which is comprised of more than one
             PI

          -  Inclusion of an NNRTI in the PI-containing regimen

          -  Prisoners or subjects involuntary incarcerated for treatment of psychiatric or
             physical illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2003</study_first_submitted>
  <study_first_submitted_qc>August 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2003</study_first_posted>
  <disposition_first_submitted>January 28, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>January 28, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 1, 2010</disposition_first_posted>
  <last_update_submitted>April 7, 2011</last_update_submitted>
  <last_update_submitted_qc>April 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2011</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

